2021
DOI: 10.1016/j.msec.2020.111774
|View full text |Cite
|
Sign up to set email alerts
|

Tailoring functional nanostructured lipid carriers for glioblastoma treatment with enhanced permeability through in-vitro 3D BBB/BBTB models

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
13
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

1
8

Authors

Journals

citations
Cited by 32 publications
(14 citation statements)
references
References 97 publications
1
13
0
Order By: Relevance
“…The particles were polydisperse: modal sizes were 109.4 and 126.5 nm for THC-SLNs and blank SLNs, respectively. This is in line with previous reports showing larger particles for blank nanostructured lipid carriers (NLCs) due to their lack of a dense drug core [45,46]. FTIR was used to investigate the interplay and interactions between drug and lipid during the preparation of SLNs (Figure 2).…”
Section: Nanoparticle Tracking Analysis (Nta)supporting
confidence: 85%
“…The particles were polydisperse: modal sizes were 109.4 and 126.5 nm for THC-SLNs and blank SLNs, respectively. This is in line with previous reports showing larger particles for blank nanostructured lipid carriers (NLCs) due to their lack of a dense drug core [45,46]. FTIR was used to investigate the interplay and interactions between drug and lipid during the preparation of SLNs (Figure 2).…”
Section: Nanoparticle Tracking Analysis (Nta)supporting
confidence: 85%
“…However, those with PDI values more than 0.5 are described as heterogeneous and polydispersed (broad distribution). In most cases, PDI values less than 0.3 are considered the optimum for SLNs and NLCs [107].…”
Section: Particle Sizementioning
confidence: 99%
“…Recent and innovative works with DTX in NLC have been reported, such as that by Zwain et al [41] in which pegylated NLC were prepared by changing the concentrations or combining liquid lipids (Labrasol, Lauroglycol 90, Capryol and Kolliphor HS15) to enhance drug permeability through the blood-brain barrier (BBB). For the treatment of glioblastoma, the authors used 3D BBB/blood-brain tumour barrier (BBTB) in vitro models and combined optimised formulations with four liquid lipids at low concentrations to increase permeation to the central nervous system.…”
Section: Cabazitaxelmentioning
confidence: 99%